MENU
+Compare
TKPHF
Stock ticker: OTC
AS OF
Oct 9 closing price
Price
$27.17
Change
-$1.83 (-6.31%)
Capitalization
55.07B

TKPHF stock forecast, quote, news & analysis

Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4... Show more

TKPHF
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for TKPHF with price predictions
Feb 03, 2026

Aroon Indicator for TKPHF shows an upward move is likely

TKPHF's Aroon Indicator triggered a bullish signal on January 29, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 168 similar instances where the Aroon Indicator showed a similar pattern. In of the 168 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for TKPHF moved above the 200-day moving average on January 09, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

TKPHF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for TKPHF moved out of overbought territory on January 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Momentum Indicator moved below the 0 level on January 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TKPHF as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for TKPHF turned negative on January 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.000) is normal, around the industry mean (29.792). P/E Ratio (68.445) is within average values for comparable stocks, (74.095). Projected Growth (PEG Ratio) (0.341) is also within normal values, averaging (2.035). Dividend Yield (0.042) settles around the average of (0.029) among similar stocks. P/S Ratio (1.736) is also within normal values, averaging (116.680).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TKPHF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TKPHF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

A.I.Advisor
published Dividends

TKPHF paid dividends on December 01, 2020

Takeda Pharmaceutical Co., Ltd. TKPHF Stock Dividends
А dividend of $90.00 per share was paid with a record date of December 01, 2020, and an ex-dividend date of September 29, 2020. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.75B. The market cap for tickers in the group ranges from 2.12K to 64.79B. MKKGY holds the highest valuation in this group at 64.79B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -2%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 14%. CABR experienced the highest price growth at 27%, while SXTC experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 18%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was -67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 63
Price Growth Rating: 58
SMR Rating: 80
Profit Risk Rating: 89
Seasonality Score: -19 (-100 ... +100)
View a ticker or compare two or three
TKPHF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
1-1, Nihonbashi-Honcho 2-Chome
Phone
+81 332782306
Employees
49095
Web
https://www.takeda.com